Analysts expect revenue increase Amgen

Tomorrow the American Amgen will publish its past quarter's figures. For this year Amgen 's revenue will be around 23,17 billion USD. This is according to the average of the analysts' estimates. This is slightly more than 2017's revenue of 22,85 billion USD.

Historical revenues and results Amgen plus estimates 2018

The analysts expect for 2018 a net profit of 9,39 billion USD. The majority of the analysts expects for this year a profit per share of 14,01 USD. So the price/earnings-ratio equals 13,43.

Per share the analysts are expecting a dividend of 5,21 USD per share. The dividend yield is then 2,77 percent. The average dividend yield of the biotech companies equals a limited 0,5 percent.

Newest target prices around 208 USD

The most recent recommendations for the biotech company are from Morgan Stanley , JP Morgan and Jefferies & Co..

Based on the current number of outstanding shares Amgen 's market capitalization is 138,92 billion USD. The Amgen stock was the past 12 months quite unstable. Since last October the stock is 11 percent higher. This year the stock price moved between 163 and 210 dollar. Since 2008 the stock price is almost 211 percent higher.

On Monday the stock closed at 188,19 USD.

Historical stock prices Amgen2007-2018

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.